Cancer Biotherapy and Radiopharmaceuticals

Aims & Scope

Cancer Biotherapy and Radiopharmaceuticals provides peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer.

It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.

The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.

Cancer Biotherapy and Radiopharmaceuticals coverage includes: Antibody drug conjugates Fusion toxins and immunotoxins Nanoparticle therapy Vascular therapy Inhibitors of proliferation signaling pathways.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.1
2024	2.40

Journal Rank

Year	Value
2024	10573

Journal Citation Indicator

Year	Value
2024	666

SJR (SCImago Journal Rank)

Year	Value
2024	0.550

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	72

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs

  Citation: 296

  Authors: Aicha, Tammy, Steve, Kandasamy, Nabil, Benjamin

• Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research

  Citation: 234

  Authors: Carolyn J., Riccardo

• Growing Applications of “Click Chemistry” for Bioconjugation in Contemporary Biomedical Research

  Citation: 197

  Authors: Kido, Martin W.

• Affinity and Avidity in Antibody-Based Tumor Targeting

  Citation: 150

  Authors: Stephen I., Gregory P.

• Structure and Function of Bone Marrow Hemopoiesis: Mechanisms of Response to Ionizing Radiation Exposure

  Citation: 146

  Authors: T.M., D., C., K.

• A Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti<i>α</i>_v<i>β</i>₃) Antibody in Patients with Metastatic Cancer

  Citation: 137

  Authors: James A., M. B., Alma, Mansoor N., Chin Yu, William, Albert F.

• Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu DOTA-TATE and ¹⁷⁷Lu DOTA-NOC

  Citation: 134

  Authors: Christiane, Stefan, Carolin, Dirk, Richard P.

• Paclitaxel (Taxol): An Inhibitor of Angiogenesis in a Highly Vascularized Transgenic Breast Cancer

  Citation: 123

  Authors: Derick H., Ling, Lawrence J., Patricia A., Anthony T.

• Feasibility of Dosimetry-Based High-Dose ¹³¹I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic Neuroblastoma

  Citation: 120

  Authors: Mark N., Yen-Ch'ing, Glenn D., Rob J., Frank H., Simon T.

• Cancer Immunotherapy

  Citation: 114

  Authors: Robert O.

---